Introduction: Lymphoepithelioma-like carcinoma of the bladder (LELC-B) is a rare variant of bladder tumors and until today only 145 cases are reported in the literature. It has a worse prognosis and survival rates in comparison with papillary muscle invasive tumors. However, general treatment options including radical cystectomy, chemotherapy and radiotherapy; discovery of the programmed death cell ligand-1 (PDL-1) expression for LELC-B recently, may lead a novel immunohistochemical diagnostic method and PDL-1 immunostaining may increase detection of this variant. Case Presentation: A 72-year-old male patient with lower urinary tract symptoms is diagnosed as bladder tumor with imaging modalities. After transurethral resection of this bladder tumor, immunopathological diagnose was muscle invasive bladder tumor predominantly lymphepithelioma like carcinoma of the bladder. PDL-1 immunostaining was also highly positive(>%50). Discussion/Conclusion: Lymphoepithelioma-like cancer of bladder is an undifferantiated aggressive rare variant of bladder cancers. Its identifiability may increase with detection of PDL-1 expression. In the future, that might pave a road to targeted immunotherapies as an alternative for selected patients.